Floatz logo

MP0533

Acute

Molecular Partners AGPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Acute cohort.

Asset / SponsorPhaseRating
Paliperidone Palmitate 3-Month Formulation
Janssen Cilag N.V./S.A.
Phase 4BB
Vosaroxin
Sunesis Pharmaceuticals
Phase 2B
Tenecteplase
ProMedica Health System
Phase 2/3B
Venetoclax
Molecular Partners AG
Phase 1/2CCC
Azacitidine
Molecular Partners AG
Phase 1/2CCC

View all 9 →

Same molecule, other indications

MP0533 is also rated in:

myeloid neoplasmDormant
CCC
Indicative ·
48 / 100
View asset →
Newly DiagnosedDormant
CC
Indicative ·
45 / 100
View asset →
leukemiaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →